Company Overview and News

 
Almadex Minerals Ltd. and Azucar Minerals Ltd. Announce Closing of Arrangement

2018-05-18 globenewswire
VANCOUVER, British Columbia, May 18, 2018 (GLOBE NEWSWIRE) -- Almadex Minerals Limited (“Old Almadex”) is pleased to announce that it has closed the previously announced statutory plan of arrangement (the “Plan of Arrangement”) under Section 288 of the Business Corporations Act (British Columbia) to spin-out Old Almadex’s early stage exploration projects, royalty interests, and certain other assets into Almadex Minerals Ltd.

1
Almaden Announces $7 Million Non-Brokered Private Placement

2018-05-11 globenewswire
VANCOUVER, B.C., May 11, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden” or “the Company”) (TSX:AMM) (NYSE American:AAU) is pleased to announce a proposed non-brokered private placement financing (the "Offering") of up to 7,000,000 units (the “Units”) to raise up to $7,000,000 at a price of $1.00 per Unit.

1
Almadex Shareholders Approve Spinout Transaction; Almadex Updates Transaction Timing

2018-05-08 globenewswire
VANCOUVER, British Columbia, May 08, 2018 (GLOBE NEWSWIRE) -- Almadex Minerals Limited (“Almadex” or the “Company”); (TSX-V:AMZ); (OTCQX:AXDDF) is pleased to announce that shareholders at its Special Meeting of shareholders held today in Vancouver have voted 99.97% in favour of a special resolution approving a statutory plan of arrangement (the “Plan of Arrangement”) under Section 288 of the Business Corporations Act (British Columbia) to spin-out Almadex’s early stage exploration projects, royalty interests, and certain other assets into 1154229 B.

 
Abacus Announces Start of Drilling at Willow in Nevada

2018-04-24 globenewswire
VANCOUVER, British Columbia, April 24, 2018 (GLOBE NEWSWIRE) -- Abacus Mining & Exploration Corporation (“Abacus” or the “Company”) (TSXV:AME) is pleased to announce that a diamond drill is presently being mobilized to the Company’s Willow and adjacent Nev-Lorraine properties in the Yerington, Nevada copper camp.

 
Almadex Provides Update On Spin-Out Transaction and Newcrest Investment

2018-04-16 globenewswire
VANCOUVER, British Columbia, April 16, 2018 (GLOBE NEWSWIRE) -- Almadex Minerals Limited (“Almadex” or the “Company”) (TSX-V:AMZ) (OTCQX:AXDDF) announces that, further to its news release dated February 26, 2018, the Company has mailed and filed its Notice of Special Meeting of Shareholders (the “Meeting”) and the related Management Information Circular (the “Circular”) which describes, amongst other things, the proposed spin-out of Almadex’s early stage exploration projects, royalty interests and certain other assets, into a new public company (“Spinco”).

 
AXDDF / ALMADEX MINERALS LTD. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-04-11 fintel.io
ALMADEX MINERALS LTD. (OTC:AXDDF) has 3 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,955,959 shares. Largest shareholders include Global Strategic Management Inc, Tocqueville Asset Management L.p., and CHURCHILL MANAGEMENT Corp.

 
Almaden Files Form 20-F Documentation

2018-03-29 globenewswire
VANCOUVER, British Columbia, March 28, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden” or “the Company”) (TSX:AMM) (NYSE American:AAU) announces that its Form 20-F for the fiscal year ended December 31, 2017 has been filed with the U.S. Securities and Exchange Commission. The Form 20-F and the Company's audited consolidated financial statements for the years ended December 31, 2017 and 2016 are available on the Company's website at http://www.

 
Almadex Minerals Announces Closing of $5.6 Million Non-Brokered Private Placement

2018-03-28 globenewswire
VANCOUVER, B.C. , March 27, 2018 (GLOBE NEWSWIRE) -- Almadex Minerals Limited (“Almadex” or the “Company”) (TSX-V:AMZ) (OTCQB:AXDDF) is pleased to announce that it has closed its previously announced non-brokered private placement with the issuance of 4,000,000 units (“Units”) at $1.40 per Unit. Each Unit consists of one common share of the Company and one-half of one non-transferable common share purchase warrant (each such whole share purchase warrant, a “Warrant”).

 
Almaden Updates Feasibility Study at Ixtaca

2018-03-21 globenewswire
VANCOUVER, British Columbia, March 21, 2018 (GLOBE NEWSWIRE) -- Almaden Minerals Ltd. (“Almaden” or “the Company”) (NYSE American:AAU) (TSX:AMM) is pleased to update investors on the environmental and engineering work relating to the feasibility study (FS) at the Ixtaca gold-silver project located in Puebla State, Mexico.

 
BRIEF-Almadex Proposed Non-Brokered Private Placement To Raise About $5.6 Mln

2018-03-01 reuters
* ALMADEX MINERALS - PROPOSED NON-BROKERED PRIVATE PLACEMENT FINANCING OF UP TO 4 MILLION UNITS TO RAISE ABOUT $5.6 MILLION AT PRICE OF $1.40 PER UNIT Source text for Eikon: Further company coverage:

2
Almadex Minerals Is Extraordinarily Undervalued

2018-03-01 seekingalpha
Almadex Minerals (OTCQX:AXDDF) was formed as a spin-off from Almaden Minerals (AAU) in mid-2015. Almadex is comprised of several exploration properties plus Net Smelter Royalty interests on projects managed by other companies. The idea behind the original transaction was that the value of the parts was greater than the sum of the parts under one corporate umbrella.

13
Top 20 Gold Mining Stocks For 2018

2018-01-02 seekingalpha
Above are my Top 20 gold mining stocks for 2018. All of these companies have large resources and are highly undervalued based on their cash flow potential at higher gold prices. They are on this list primarily because of their upside potential. These are either producers or development stocks, although there is one optionality play (Goldmining Inc).

 
Almaden Hits 16.40 m of 2.25 g/t Gold and 25.3 g/t Silver and 10.50 m of 2.45 g/t Gold and 24.4 g/t Silver in Upper Portion of PFS Pit

2017-12-20 marketwired
VANCOUVER, BC--(Marketwired - December 20, 2017) - Almaden Minerals Ltd. ("Almaden" or "the Company") (TSX: AMM) (NYSE MKT: AAU) (NYSE American: AAU) is pleased to announce new assay results from Almaden's ongoing exploration and development program at the Company's Tuligtic project, Mexico. Today's results are from holes TU-17-508, 517, 521, 522, 524, 525, 526 and 528 which were drilled to follow-up hole TU-17-504 (announced August 23, 2017) that intersected new and significant mineralisation in an upper portion of the Pre-Feasibility Study ("PFS") pit which was modelled as waste material in the Company's PFS.

 
Almadex Intersects Enriched Copper at Raya Tembrillo (Villa Rica) Cuts 94.00 M of 1.36% Copper and 0.07 G/T Gold Including 43.00 M of 2.45% Copper and 0.09 G/T Gold

2017-12-13 marketwired
VANCOUVER, BC--(Marketwired - December 13, 2017) - Almadex Minerals Limited ("Almadex" or the "Company") (TSX VENTURE: AMZ) (OTCQX: AXDDF) is pleased to announce it has received assay results from holes EC-17-036 and 041 from the Raya Tembrillo area which is the very northern part of the large Villa Rica Zone of the El Cobre property. This area is located approximately two kilometers south of the Norte Zone where since 2016 most of our drilling on the El Cobre property has been focussed.

 
Almaden Announces Completion of Social Impact Assessment at Ixtaca Project

2017-12-12 marketwired
VANCOUVER, BC--(Marketwired - December 12, 2017) - Almaden Minerals Ltd. ("Almaden" or "the Company")(TSX: AMM) (NYSE American: AAU) (NYSE MKT: AAU) is pleased to announce that in the Spring of 2017 it engaged an arms-length consultant to conduct a Social Impact Assessment ("SIA") of the Ixtaca Project. Almaden has now received a summary report of the SIA, which provides objective insight into the degree to which community members understand the Ixtaca project, and provides a valuable road map for further interactions with the communities who live local to the Ixtaca project area in Puebla State, Mexico.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...